Liver Transplant and Incisional Hernia: What Do We Know and What Can We Improve

被引:0
|
作者
Bastante, Mireia Dominguez [1 ,2 ]
Osuna, Maria Carmen Montes [1 ]
Rosello, Alfonso Mansilla [1 ]
del Moral, Jesus Villar [1 ]
机构
[1] Univ Hosp Virgen Nieves, Gen Surg & Liver Transplantat Unit, Granada, Spain
[2] Univ Hosp Virgen Nieves, Avda Fuerzas Armadas SN, Granada 18014, Spain
关键词
RISK-FACTORS; CLOSURE;
D O I
10.1016/j.transproceed.2023.09.003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. During follow-up, incisional hernias can reduce the quality of life of transplant recipients. The objective was to analyze the incidence of incisional hernia and risk factors to detect improvements.Methods. Retrospective study of transplant recipients between 2002 and 2021. The diagnosis of incisional hernia was clinical and/or radiological. Demographic variables, risk factors, and incisional hernias were studied. Absolute and relative frequency measures have been calculated for qualitative variables and central tendency and dispersion in cases of numerical ones. A multivariate study was performed to identify incisional hernia predictors. were not clinically diagnosed. Multivariate analysis revealed that overweight (hazard ratio [HR] 1.36; 95% CI 0.72-2.56), obesity (HR 2.36; 95% CI 1.26-4.42), transfusion platelet (3% increase per concentrate), smoking history (HR 1.71; 95% CI 0.99-2.964), immunosuppression induction with everolimus (HR 4.43; 95% CI 1.61-12.16), and maintenance with sirolimus (HR 2.34; 95% CI 1.21-4.52) were risk factors for developing incisional hernia.Conclusions. The wide interval of incidence of incisional hernia reflects diagnostic inconsistencies. Incisional hernias should be known by clinicians and patients due to their possible complications. There are significant risk factors related to unhealthy lifestyle habits that are modifiable. Carrying out "small bites" as a closure technique could improve theresults. Patients with other no-modifiable factors should be closely followed up. Incisional hernia is frequent and underdiagnosed. Healthy lifestyle habits should be promoted and corrected. Patients with nonmodifiable factors should be closely monitored.
引用
收藏
页码:2278 / 2281
页数:4
相关论文
共 50 条
  • [21] Bacterial Vaginosis: What Do We Currently Know?
    Abou Chacra, Linda
    Fenollar, Florence
    Diop, Khoudia
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 11
  • [22] What we know, what we do not know, and what we should and could have known about workplace bullying: An overview of the literature and agenda for future research
    Nielsen, Morten Birkeland
    Einarsen, Stale Valvatne
    AGGRESSION AND VIOLENT BEHAVIOR, 2018, 42 : 71 - 83
  • [23] The Dawn of Mitophagy: What Do We Know by Now?
    Belousov, Dmitrii M.
    Mikhaylenko, Elizaveta, V
    Somasundaram, Siva G.
    Kirkland, Cecil E.
    Aliev, Gjumrakch
    CURRENT NEUROPHARMACOLOGY, 2021, 19 (02) : 170 - 192
  • [24] Anthocyanins: What do we know until now?
    Giampieri, Francesca
    Cianciosi, Danila
    Alvarez-Suarez, Jose M.
    Quiles, Jose L.
    Forbes-Hernandez, Tamara Y.
    Navarro-Hortal, Maria D.
    Machi, Michele
    Pali Casanova, Ramon del Jesus
    Martinez Espinosa, Julio Cesar
    Chen, Xiumin
    Di Zhang
    Bai, Weibin
    Tian Lingmin
    Mezzetti, Bruno
    Battino, Maurizio
    Diaz, Yasmany Armas
    JOURNAL OF BERRY RESEARCH, 2023, 13 (01) : 1 - 6
  • [25] Circadian Rhythm and Glaucoma: What do We Know?
    Ciulla, Lauren
    Moorthy, Meena
    Mathew, Sunu
    Siesky, Brent
    Verticchio Vercellin, Alice C.
    Price, David
    Januleviciene, Ingrida
    Harris, Alon
    JOURNAL OF GLAUCOMA, 2020, 29 (02) : 127 - 132
  • [26] What can We Know about Unanswerable Questions?
    Raleigh, Thomas
    PHILOSOPHICAL QUARTERLY, 2023, 75 (01) : 213 - 227
  • [27] Bones and muscular dystrophies: what do we know?
    Wood, Claire L.
    Straub, Volker
    CURRENT OPINION IN NEUROLOGY, 2018, 31 (05) : 583 - 591
  • [28] Nipah virus disease: what can we do to improve patient care?
    Hassan, Md Zakiul
    Shirin, Tahmina
    Satter, Syed M.
    Rahman, Mohammed Z.
    Bourner, Josephine
    Cheyne, Ashleigh
    Torreele, Els
    Horby, Peter
    Olliaro, Piero
    LANCET INFECTIOUS DISEASES, 2024, 24 (07) : e463 - e471
  • [29] Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go?
    Aprotosoaie, Ana Clara
    Costache, Alexandru-Dan
    Costache, Irina-Iuliana
    PHARMACEUTICS, 2022, 14 (04)
  • [30] Long-term complications of type 1 diabetes: what do we know and what do we need to understand?
    Piona, Claudia
    Ventrici, Claudia
    Marcovecchio, Loredana
    Chiarelli, Francesco
    Maffeis, Claudio
    Bonfanti, Riccardo
    Rabbone, Ivana
    MINERVA PEDIATRICS, 2021, 73 (06): : 504 - 522